Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 14;19(1):151.
doi: 10.1186/s12885-019-5354-5.

Risk and Consequences of Chemotherapy-Induced Thrombocytopenia in US Clinical Practice

Free PMC article

Risk and Consequences of Chemotherapy-Induced Thrombocytopenia in US Clinical Practice

Derek Weycker et al. BMC Cancer. .
Free PMC article


Background: Chemotherapy-induced thrombocytopenia (CIT) is a potentially serious complication that can lead to chemotherapy dose delays, dose reductions, or discontinuation, and increases the risk of serious bleeding events. The objectives of this study were to characterize the incidence, clinical consequences, and economic costs of CIT in current US clinical practice.

Methods: A retrospective cohort design and data from two US private healthcare claims repositories (01/2010-12/2016) were employed. Study population comprised adults who received selected myelosuppressive chemotherapy regimens for solid tumors or non-Hodgkin's lymphoma. CIT was identified based on: diagnosis code for thrombocytopenia or bleeding; procedure code for platelet transfusion or bleeding control; or drug code for thrombopoietin-receptor agonist. Incidence of CIT was evaluated during the chemotherapy course (max. no. cycles = 8), and associated consequences and costs (2016US$) were evaluated during the cycle of the CIT episode.

Results: Among 215,508 cancer chemotherapy patients, CIT incidence during the course (mean no. cycles = 4.6) was 9.7% (95% CI: 9.6-9.8), and ranged from 6.1% (5.9-6.3) for regimens containing cyclophosphamide to 13.5% (12.7-14.3) for regimens containing gemcitabine; among all patients, incidence was 2.7% (2.6-2.8) in cycle 1, 2.7% (2.6-2.8) in cycle 2, and 2.9% (2.9-3.0) in cycles thereafter. One-third of CIT episodes were managed in hospital, and for the subset of patients hospitalized with a first-listed diagnosis of CIT, mean length of stay was 4.6 (4.4-5.0) days and mean cost of inpatient care was $36,448 (32,332-41,331). Across cycles with CIT, mean cost of CIT-related care was $2179 (2029-2329), comprising $1024 (881-1167) for inpatient care and $1153 (1119-1187) for outpatient care.

Conclusions: In this retrospective evaluation of cancer chemotherapy patients, CIT incidence was high, especially among patients receiving gemcitabine-based regimens, and the costs of CIT-related care were substantial. Accordingly, interventions aimed at identifying and targeting high-risk patients for preventative measures may yield substantial clinical and economic benefits.

Keywords: Bleeding; Chemotherapy-induced thrombocytopenia; Myelosuppressive chemotherapy; Thrombopoietin-receptor agonist.

Conflict of interest statement

Ethics approval and consent to participate

The data extracts were de-identified prior to their release to study investigators, and thus their use for health services research is compliant with the HIPAA Privacy Rule and federal guidance on Public Welfare and the Protection of Human Subjects. This research is thus exempt from IRB review.

Consent for publication

Not applicable.

Competing interests

Aaron Grossman, Ahuva Hanau, Alexander Lonshteyn, and Derek Weycker are employed by PAI. David Chandler, Mark Hatfield, and Anjali Sharma are employed by, and own stock in, Amgen Inc.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

See all similar articles

Cited by 1 article


    1. Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park) 2015;29:282–294. - PubMed
    1. Wu Y, Aravind S, Ranganathan G, Martin A, Nalysnyk L. Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007. Clin Ther. 2009;31:2416–2432. doi: 10.1016/j.clinthera.2009.11.020. - DOI - PubMed
    1. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist. 2001;6(Suppl 5):15–23. doi: 10.1634/theoncologist.6-suppl_5-15. - DOI - PubMed
    1. Hitron A, Steinke D, Sutphin S, Lawson A, Talbert J, Adams V. Incidence and risk factors of clinically significant chemotherapy-induced thrombocytopenia in patients with solid tumors. J Oncol Pharm Pract. 2011;17:312–319. doi: 10.1177/1078155210380293. - DOI - PubMed
    1. Elting LS, Cantor SB, Martin CG, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer. 2003;97:1541–1550. doi: 10.1002/cncr.11195. - DOI - PubMed

MeSH terms